Add this topic to your myFT Digest for news straight to your inbox
Changes are likely to affect drugs for very rare diseases
Analysts’ targets already reflect the expectation that sales and earnings growth will accelerate
Billionaire returns to prominence with pharma venture
High-yielding multinationals offer balance of risk and return
The former Daewoo Motor executive is making waves in the drug industry, writes Song Jung-a
Rob Hardy believes Aesica’s success proves British manufacturing can thrive
Mitch Daniels has strong record of budgetary success
What the doctor ordered for Cephalon shareholders
Big pharma is a shrinking business
New entrants to the pharmaceutical industry do not exist
International Edition